Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NRX4

UPID:
PHP14_HUMAN

ALTERNATIVE NAMES:
Phosphohistidine phosphatase 1; Protein histidine phosphatase; Protein janus-A homolog

ALTERNATIVE UPACC:
Q9NRX4; B1AMX0; B1AMX1; Q9H0Y3

BACKGROUND:
14 kDa phosphohistidine phosphatase, with alternative names such as Phosphohistidine phosphatase 1, exhibits phosphohistidine phosphatase activity, underscoring its importance in protein phosphorylation and dephosphorylation processes. These processes are crucial for the regulation of various cellular functions, indicating the enzyme's central role in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions and mechanisms of 14 kDa phosphohistidine phosphatase offers a promising avenue for the development of novel therapeutic approaches. The enzyme's activity in phosphorylation regulation highlights its potential as a target in conditions where altered phosphorylation is a hallmark.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.